Skip to main content

Advertisement

Table 2 Dose intensity, Grade 3/4 adverse events and objective tumor responses.

From: Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

ID Number Number of Completed Cycles Total Cumulative Dose (mg) Grade 3/4 Adverse Events Objective Response
0001–1103 2 46.8 None PD
0002–2101 1 23.7 None PD
0002–2102 2 17.0 ALP NOS increased Amylase increased Lipase increased Liver function tests NOS increased PD
0003–3101 2 54.0 None PD
0003–3102 2 45.1 Ureteric obstruction PD
0004–4101 4 115.2 Pyrexia Rigors Hyponatremia Hypoxia SD × 4 mo.
0004–4102 2 42.7 Pyrexia Rigors PD
0004–4103 2 43.6 ALT increased Hypokalemia Rash NOS PD
0004–4104 4 85.4 Arthralgia Rigors SD × 4 mo.
  1. PD = progressive disease. SD = stable disease. ALP = alkaline phosphatase. NOS = not otherwise specified. ALT = alanine aminotransferase.